Dr. Carson joined atai Life Sciences in 2022.
Previously, Dean was Vice President of Scientific Affairs at Saniona, Inc. a Copenhagen headquartered biotech company developing ion-channel targeting compounds for CNS and rare diseases. He was a key member of the financing team responsible for raising significant funds to build out Saniona’s Boston office and was a senior member of the clinical development team that successfully shepherded several compounds through late-stage preclinical research and early to mid-stage clinical development.
Prior to that he was Founder/CEO of Katana Pharmaceuticals, Inc., a San Francisco based biotech focused on the development of novel treatments for underserved neonatal and pediatric conditions. Katana’s assets were successfully acquired in 2020. He has held several other senior management positions, including as Director of Translational Medicine at the Stanford spin-off Trigemina, Vice President of US Operations for the Australian neurotech Anatomics, and was a senior medical affairs contractor for Janssen where he was involved in the commercial launch of SPROVATO® (esketamine) for treatment resistant depression.
Dean is a neuroscientist and psychopharmacologist. He holds a bachelor’s degree in psychology and behavioral neuroscience from the University of New South Wales, a PhD in neuropharmacology from the University of Sydney, and completed a postdoctoral research fellowship in psychiatry and behavioral sciences at Stanford University.